ONCAlert | 2018 ASCO Annual Meeting
Videos  >  

Results for Neratinib Plus Capecitabine in HER2+ Breast Cancer Brain Metastases

Rachel A. Freedman, MD, MPH
Published Online:6:45 PM, Wed July 5, 2017

Rachel A. Freedman, MD, MPH, associate clinical director, Breast Oncology Center, Susan F. Smith Center for Women's Cancers, Dana-Farber Cancer Institute, senior physician, assistant professor of medicine, Harvard Medical School, discusses a phase II trial of neratinib plus capecitabine for patients with HER2-positive breast cancer brain metastases.
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.